Medical Condition News

RSS

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular events associated with SYMLIN (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.

28 Jun 2010

12 new gene variants that impact individual's risk of developing type 2 diabetes identified

An international consortium including Helmholtz Zentrum München and the German Diabetes Center, Düsseldorf has identified 12 new gene variants which impact the individual's risk of developing type 2 diabetes. The study represents a major contribution towards elucidating the complex pathogenesis of this important widespread disease. Nature Genetics has published the findings of this study in its current issue.

28 Jun 2010

Gastric bypass surgery can help improve ratio of total cholesterol to HDL cholesterol: Study

Gastric bypass surgery can help lower cholesterol and improve the ratio of total cholesterol to HDL (good) cholesterol, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

28 Jun 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

28 Jun 2010

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zila, leader in the prevention and detection of oral diseases, today introduced an angled exam mirror as part of the ViziLite Plus oral lesion identification and marking system. The autoclavable mirror attaches to the top of the ViziLite Plus lightstick retractor, enhancing dental professionals' ability to see oral lesions during a comprehensive oral cancer screening procedure.

28 Jun 2010

Cartilage loss plays a role in development of OA, study says

A recent study determined that bone area predicted the development of medial (inner side) and lateral (outer side) knee cartilage damage and loss of medial cartilage volume. Subchondral bone mineral density (BMD) was associated with medial defect development but not cartilage loss. Researchers believe subchondral bone changes and loss of cartilage contribute to the development of osteoarthritis (OA).

28 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Dark chocolate reduces blood pressure in people with hypertension

For people with hypertension, eating dark chocolate can significantly reduce blood pressure. Researchers writing in the open access journal BMC Medicine combined the results of 15 studies into the effects of flavanols, the compounds in chocolate which cause dilation of blood vessels, on blood pressure.

28 Jun 2010

Increased follow-up care proves key to helping depressed patients feel better

New data released by two non-profit health care organizations, MN Community Measurement and the Institute for Clinical Systems Improvement, indicate that Minnesota providers only slightly improved their quality of care for patients with depression from a year ago, but that new programs that increase clinic contact with the patient demonstrate the potential for much better results moving forward.

28 Jun 2010

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

The University of California Santa Barbara (UCSB) and Sansum Diabetes Research Institute (Sansum) announced today the achievement of a milestone in the Artificial Pancreas Project funded by the Juvenile Diabetes Research Foundation (JDRF).

28 Jun 2010

New research finds key proteins involved in the process of memory and learning

New research led by the University of Leicester and published in a prestigious international scientific journal has revealed for the first time the mechanism by which memories are formed.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Cells in immune system react to stomach ulcer bacterium Helicobacter pylori, identify researchers

Researchers have identified cells in the immune system that react to the stomach ulcer bacterium Helicobacter pylori, one of the risk factors for the development of stomach cancer. This discovery could lead to faster diagnosis and treatment as well as a better prognosis for patients with stomach cancer, reveals a thesis from the University of Gothenburg, Sweden.

28 Jun 2010

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical Corp. announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

28 Jun 2010

Medical Condition News

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

12 new gene variants that impact individual's risk of developing type 2 diabetes identified

Gastric bypass surgery can help improve ratio of total cholesterol to HDL cholesterol: Study

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Cartilage loss plays a role in development of OA, study says

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

ADVANCE study provides new insights into the management of SHPT in CKD patients

Dark chocolate reduces blood pressure in people with hypertension

Increased follow-up care proves key to helping depressed patients feel better

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

New research finds key proteins involved in the process of memory and learning

Linagliptin mono- and combination therapy improves blood glucose control

Cells in immune system react to stomach ulcer bacterium Helicobacter pylori, identify researchers

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News